BSE filing, NSE: SOLARA. Summary written from the filing by ALFA Finder's alert engine.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹653.80
- Market cap
- ₹3,149 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- 85.3×Sector 46.1×
- Promoter holding
- 41.93%+0.00% QoQ
- FII holding
- 10.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara Active Pharma Sciences Investor Presentation: Key Takeaways
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara Active Pharma Sciences Employee Stock Options
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
- Value
- ₹0.31 Cr
Solara Active Pharma Sciences Q2 FY27 Results: Turns Profitable, Net Profit ₹28.5 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹28.5 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.